Shuhei Moriguchi

Squamous cell transformation as a mechanism of acquired resistance to tyrosine kinase inhibitor in EGFR‐mutated lung adenocarcinoma: a report of two cases

Hironori Uruga, Takeshi Fujii, Nobuyuki Nakamura et al. · Respirology Case Reports · 2020 · 16 citations · Full text

Medicine, Molecular Biology, Oncology +17

Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia

Kazutoshi Isobe, Yasuhiko Nakamura, Susumu Sakamoto et al. · ERJ Open Research · 2024 · 14 citations · Full text

Medicine, Oncology, Pharmacology +15

Transformation of epidermal growth factor receptor T790M mutation‐positive adenosquamous carcinoma of the lung to small cell carcinoma and large‐cell neuroendocrine carcinoma following osimertinib therapy: an autopsy case report

Shuhei Moriguchi, Hironori Uruga, Takeshi Fujii et al. · Respirology Case Reports · 2019 · 12 citations · Full text

Medicine, Oncology, Pathology +17

Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis

Hironori Uruga, Shuhei Moriguchi, Yui Takahashi et al. · BMC Cancer · 2018 · 11 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) to predict succeeding onset of immune-related adverse events (irAEs).

Rika Kizawa, Yuji Miura, Yasuhiro Oda et al. · Journal of Clinical Oncology · 2019 · 11 citations

Life Sciences, Immunology, Oncology +17